iwCLL 2023 | Improving outcomes of non-covalent BTKi treatment
Varsha Gandhi
• 7 Oct 2023
In this interview, Varsha Gandhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, summarizes the different strategies for improving efficacy of non-covalent BTK inhibitor (BTKi) treatment. These include using non-covalent BTKi’s in patients who have not been previously treated with covalent BTKi’s, and combining or sequencing agents to resensitize cells and produce improved disease outcomes. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
